secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-06-10T20:27:32+00:00
Accession:  0001628280-26-042237
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology appoints Timothy Coughlin as new director and Audit Committee Chair
--------------------------------------------------------------------------------

- Board increased from 7 to 8 members; Timothy Coughlin appointed effective June 9, 2026.
- Coughlin named Chair of the Audit Committee immediately upon appointment.
- Will receive standard non-employee director cash and equity per company policy; no related-party transactions.
- Received automatic stock option and RSU awards under the 2019 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026042237/0001628280-26-042237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026042237/vir-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-042237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer